Alexander V. Kabanov

This paper introduces synthetic polymer-based lipid alternatives for lipid nanoparticles, showing they can replace standard lipids while maintaining transfection activity.

ResiPOx, a nanoparticle-delivered TLR7/8 agonist, reprograms tumor-associated myeloid cells to inhibit tumor growth in mouse models of medulloblastoma and diffuse midline glioma.

This study develops PEG-free poly(2-oxazoline) lipids for LNPs, showing improved transfection, reduced liver accumulation, and enhanced immune tissue targeting in vivo.

This paper develops a safe, long-circulating iodinated lipid nanoemulsion contrast agent for CT imaging, showing improved stability, safety, and extended blood residency without nephrotoxicity.

This study shows that combining nanoformulated TLR7/8 agonist and PI3K delta inhibitor with radiotherapy improves anti-tumor activity in TNBC by modulating the tumor microenvironment.

This paper develops a nanoparticle formulation of vismodegib that improves its efficacy for medulloblastoma treatment by enhancing CNS pharmacokinetics and reducing systemic toxicity.